Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

Summary

Firstline treatment for grade 13a Follicular Lymphoma using Opdivo (nivolumab) plus Rituximab: The 1st FLOR trial

Timeline

Start

2017-09-07

Primary completion

2022-05-11

Completion

2027-06

Publications

• Barraclough A, Lee ST, Burgess M, Churilov L, Chong G, Lee D, Gilbertson M, Fancourt T, Manos K, Ritchie DS, Koldej RM, Scott AM, Keane C, Hawkes EA. Nivolumab and rituximab in treatment-naive follicular lymphoma: the phase 2 1st FLOR study. Blood Adv. 2025 Mar 25;9(6):1432-1441. doi: 10.1182/bloodadvances.2024015487.

Drugs

Indications